DBN (Beijing Dabeinong)
2025 revenue ¥29.119 bn (+1.22%) but a -¥642M net loss (turnaround year); biobreeding corn/soy advancing across major ecological zones with ≥60% domestic promotion area targeted for 2026, and a South-American "1 team + 1 R&D + 1 JV + N partners" platform with soy entering commercialization in 2026.
- Country
- China
- Ticker
- SZSE:002385
GM insect-resistant corn
Drought-tolerant soy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepamoa-china
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Climate-resilient crops | crop-biotech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.